Which companies in the biopharmaceutical M.A. market deserve attention in 2021?

After an active 2019, the biopharmaceutical market has seen an overall downward trend this year due to the outbreak.
, according to PwC, while the number of mergers and acquisitions will fall by only 2.3 per cent in 2020 compared with 2019, the overall valuation of the companies involved will fall by 60.7 per cent.
, however, AstraZeneca recently announced plans to buy Alexion Pharmaceuticals for about $39bn, making it the largest M.A. company of the year.
years and millions of dollars to develop new therapeutic drugs from zero, large pharmaceutical companies with financial advantages prefer to quickly build pipelines by acquiring innovative small and medium-sized biotech companies.
more than 10 institutions predict that the biopharmaceutical sector will see a pick-up in the M.A. market by 2021.
Yahoo Finance recently published article 4 Biotechs That Can Be Potential Targets in 2021, listing four biopharmaceutical companies that the authors consider worthy of attention.
1. BioMarin Pharmaceutical BioMarin Pharmaceutical specializes in the development of new drugs in the field of rare diseases.
company currently has six approved rare disease drugs.
BioMarin's main product, Roctavian, is a gene therapy product for haemophilia type A, which delivers functional copies of the coded coagulation factor VIII gene to the patient through the AAV5 virus vector, thus helping the patient to restore its own clotting factor VIII production capacity.
, the company announced the success of a clinical trial of vosoritide, a special-effects drug for dwarfism, in late 2019.
November, the company announced that the FDA had accepted vosoritide's new drug application (NDA), which is expected to be the first drug to treat dwarfism.
2. UniQureuniQure is dedicated to the development of gene therapies for haemophilia B, Huntington's disease, Fabry disease, spinal co-brain disorder 3 and other diseases.
last week, uniQure released the latest data from a Phase 3 clinical trial to treat haemophilia B at the annual meeting of the American Society of Hematology (ASH), which reached its main clinical endpoint and reduced bleeding rates by 83 percent.
results set the stage for uniQure to become the first biopharmaceutical company to achieve a functional cure for haemophiliac patients with type B through a one-time treatment.
3. REGENXBIOREGENXBIO is a biotechnology company dedicated to the potential of gene therapy to improve the lives of patients.
company's NAV technology platform is a proprietary adenovirus (AAV) gene delivery platform consisting of more than 100 new AAV vectors, including AAV7, AAV8, AAV9 and AAVh10.
REGENXBIO is using the platform to develop and research candidate therapies in multiple therapeutic areas.
the product in its research, RGX-314, is a gene therapy for the treatment of wet age macular degeneration, using AAV carriers to carry genetically modified proteins that can neutralize VEGF activity, and is currently in phase 1/2a clinical trials, which is expected to bring a new therapeutic experience to the patients involved.
4. Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a biopharmaceutical company dedicated to improving the lives of cancer patients by addressing key mechanisms of drug resistance.
In May, Deciphera's broad-spectrum protein kinase (KIT) and plateboard-derived growth factor α kinase (PDGFR alpha) inhibitor ripretinib were approved by the FDA for the treatment of advanced gastrointestinal mesothelioma (GIST), the world's first broad-spectrum KIT inhibitor.
Deciphera is also currently developing ripretinib for the treatment of advanced systemic hypertrophic cell hypertrophicism (ASM), gliomas and other diseases such as solid tumors induced by KIT or PDGFR alpha kinases.
Reding Pharmaceuticals last year reached an exclusive licensing agreement with Deciphera for the exclusive rights to the development and commercialization of ripretinib in Greater China.
: s1. 4 Biotechs That Can Be Potential Targets In 2021 Retrieved December 22, 2020, from